Bristol-Myers Squibb: Losing Otezla Might Be Challenging

The probable divestiture of Otezla raises concerns about the pricing of the Bristol-Myers Squibb and Celgene deal. The drug is one of Celgene’s major commercialized assets. Investors are concerned about the valuation that Otezla will secure in the divestiture considering Bristol-Myers Squibb’s urgency to complete the transaction.